Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company headquartered in San Diego, California, that focuses on the discovery and development of medicines targeting microRNAs. Its recent news flow has centered on its lead candidate, farabursen (RGLS8429), a next generation oligonucleotide designed to inhibit miR‑17 and preferentially target the kidney for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
News updates for RGLS commonly include clinical trial milestones for farabursen, such as topline data from the Phase 1b multiple-ascending dose (MAD) study in adult ADPKD patients. Regulus has reported mechanistic responses based on urinary polycystins 1 and 2 (PC1 and PC2), exploratory findings on height-adjusted total kidney volume (htTKV), and safety and tolerability data from multiple cohorts, including a fixed 300 mg dose regimen. Company releases also describe interactions with the U.S. Food and Drug Administration (FDA), including an End-of-Phase 1 meeting and alignment on key elements of a planned single pivotal Phase 3 trial with htTKV and eGFR endpoints.
Another major theme in Regulus news is corporate and transaction activity. The company announced an Agreement and Plan of Merger with Novartis AG, under which Novartis, through a subsidiary, launched a tender offer to acquire all outstanding Regulus shares for cash plus a non-tradeable contingent value right (CVR) tied to a regulatory milestone for farabursen. Subsequent disclosures report the successful completion of the tender offer and the closing of the merger, after which Regulus became an indirect wholly owned subsidiary of Novartis.
Additional RGLS news items include financial results for recent quarters and years, updates on cash runway expectations, and participation in healthcare and biotech investment conferences where management discusses the farabursen program and the company’s microRNA-targeting platform. For investors and researchers, the RGLS news page provides a consolidated view of clinical progress, regulatory interactions, transaction developments, and financial updates related to Regulus Therapeutics and its microRNA-based therapeutic strategy.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that Jay Hagan, President and CEO, will present at the 20th Annual Needham Healthcare Conference on April 15, 2021, at 1:30 P.M. ET. The event will focus on the innovative medicines targeting microRNAs developed by Regulus.
A live webcast will be accessible on the company's investor relations website, with a replay available for 30 days post-event.
Regulus Therapeutics (RGLS) reported Q4 and 2020 financial results, highlighting revenue of $5 million for the quarter and $10 million for the year, driven by milestones in their collaboration with Sanofi for RG-012. R&D expenses increased to $4 million and $15.3 million for Q4 and the year, respectively, due to ongoing development activities. The net loss narrowed to $1.3 million in Q4 and $15.7 million for the year, compared to higher losses in 2019. Regulus also completed a $19 million private financing and advanced its RGLS4326 program into Phase 1b for ADPKD.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicines, announced that its CEO, Jay Hagan, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A replay of the on-demand presentation will be accessible from March 9, 2021, on their website for 30 days. Regulus focuses on innovative drug discovery, maintaining a robust pipeline and intellectual property in the microRNA sector, headquartered in La Jolla, CA.
Regulus Therapeutics (Nasdaq: RGLS) has completed the enrollment of the first cohort in its Phase 1b clinical trial of RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This open-label study evaluates safety and pharmacokinetics, with the first cohort receiving 1mg/kg of RGLS4326. Interim safety data has led to the first patient in the second cohort receiving their dose. No serious adverse events have been reported, and results from the first cohort are anticipated in early Q2 2021.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the appointment of Alice S. Huang, Ph.D., to its board of directors, effective January 27, 2021. In addition to her board role, she will serve on the Compensation Committee. Dr. Huang is a Senior Faculty Associate at the California Institute of Technology and has an extensive background in biology and biomedical research, having held significant positions at prestigious institutions. The company believes her expertise will enhance its drug discovery and development efforts.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on microRNA-targeted medicines, will be presenting at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. Jay Hagan, President and CEO, will lead the presentation. An on-demand webcast will be accessible starting January 11, 2021, via the investor relations section of Regulus' website. The company, headquartered in La Jolla, CA, emphasizes its expertise in oligonucleotide drug discovery and holds a strong intellectual property portfolio.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the closing of a private placement, raising approximately $19.4 million by selling 24,341,607 shares of common stock at $0.622 each. Additionally, 272,970 shares of non-voting Class A-3 convertible preferred stock were sold at $6.22 per share. The proceeds will primarily support the advancement of RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease and for general corporate purposes. H.C. Wainwright and Co. acted as the exclusive placement agent for this financing.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a definitive securities purchase agreement for a private placement expected to raise approximately $19.4 million from existing and new institutional investors. The financing includes the sale of about 24.3 million shares of Common Stock priced at $0.7158 per share, along with accompanying warrants. Additionally, 272,970 shares of non-voting Class A-3 convertible preferred stock will be sold at $6.22 per share. The closing is anticipated on December 3, 2020, pending customary conditions.
Regulus Therapeutics Inc. (Nasdaq: RGLS) reported Q3 2020 financial results, highlighting a revenue increase to $5 million, up from less than $0.1 million in Q3 2019. The company announced the dosing of the first patient in its Phase 1b clinical trial for RGLS4326 targeting ADPKD. Milestones from collaboration with Sanofi, totaling $10 million, allowed a reduction of debt to $4.7 million. R&D expenses rose to $4 million, reflecting ongoing study activities. Net loss narrowed to $1.5 million, or $0.04 per share, compared to a $5.4 million loss in Q3 2019.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the achievement of a $5 million milestone from its collaboration with Sanofi for the miR-21 programs, triggered by patient enrollment in the Phase 2 clinical study of RG-012 for Alport Syndrome. This funding will reduce the term loan with Oxford LLC to approximately $4.7 million and extend interest-only payments through 2021. The company previously reported positive trends in kidney disease markers from a Phase 1b study of RG-012, which has orphan designation in both the U.S. and Europe. Additionally, Regulus is eligible for another $25 million in 2023 upon reaching a development milestone.